Centene Corporation Sued for Securities Fraud

Strategic Insights -

Investors in Centene Corporation (NYSE: CNC) who purchased company securities may be entitled to compensation after a lawsuit was filed alleging potential violations of federal securities laws. The class-action lawsuit, Lunstrum v. Centene Corporation, et al., No. 25-cv-05659, was filed in the U.S. District Court for the Southern District of New York. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Centene securities between December 12, 2024, and July 1, 2025.

Key Takeaways:

  • The lawsuit alleges that Centene misled investors about the company's financial performance by exaggerating enrollment growth and retention rates in government-sponsored healthcare programs.
  • On July 1, 2025, Centene withdrew its previous guidance after an independent actuarial report revealed lower-than-expected enrollment growth and higher-than-expected morbidity rates in the 22 of 29 states it serves.
  • The price of Centene stock fell $22.87 per share, or more than 40%, following the disclosure of the actuarial report.
  • Investing in Centene may have legal options available to investors, and a law firm is seeking to represent clients in a class-action lawsuit.
  • All representation is on a contingency fee basis, with no cost to shareholders for court costs or expenses of litigation.

Statistics:

  • The price of Centene stock fell $22.87 per share from $56.65 to $33.78 on July 2, 2025.
  • The lawsuit covers a period of time from December 12, 2024, to July 1, 2025.
  • Centene serves 29 states in the government-sponsored healthcare programs, with declines in enrollment growth and higher morbidity rates in 22 of those states.

Sources:

  • Bleichmar Fonti & Auld LLP
  • https://www.bfalaw.com/cases-investigations/centene-corporation-class-action-lawsuit
  • Newsfile Corp - September 1, 2025
  • Securities Exchange Act of 1934 (Sections 10(b) and 20(a))